JP6280033B2 - ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 - Google Patents
ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 Download PDFInfo
- Publication number
- JP6280033B2 JP6280033B2 JP2014520341A JP2014520341A JP6280033B2 JP 6280033 B2 JP6280033 B2 JP 6280033B2 JP 2014520341 A JP2014520341 A JP 2014520341A JP 2014520341 A JP2014520341 A JP 2014520341A JP 6280033 B2 JP6280033 B2 JP 6280033B2
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- alkyl
- nitro
- hydroxy
- membered ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161506848P | 2011-07-12 | 2011-07-12 | |
| US61/506,848 | 2011-07-12 | ||
| PCT/US2012/046549 WO2013010034A2 (en) | 2011-07-12 | 2012-07-12 | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524918A JP2014524918A (ja) | 2014-09-25 |
| JP2014524918A5 JP2014524918A5 (https=) | 2015-09-03 |
| JP6280033B2 true JP6280033B2 (ja) | 2018-02-14 |
Family
ID=47506934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520341A Active JP6280033B2 (ja) | 2011-07-12 | 2012-07-12 | ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10975033B2 (https=) |
| EP (1) | EP2731597B1 (https=) |
| JP (1) | JP6280033B2 (https=) |
| KR (2) | KR102050700B1 (https=) |
| CN (2) | CN103796648B (https=) |
| AU (1) | AU2012281061B2 (https=) |
| BR (1) | BR112014000810A8 (https=) |
| CA (1) | CA2844150C (https=) |
| ES (1) | ES2970814T3 (https=) |
| HU (1) | HUE065757T2 (https=) |
| MX (1) | MX383365B (https=) |
| PL (1) | PL2731597T3 (https=) |
| WO (1) | WO2013010034A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130018478A (ko) * | 2011-08-09 | 2013-02-25 | 주식회사 엘지화학 | 신규한 구조의 이차전지 팩 |
| US11400103B2 (en) | 2015-12-21 | 2022-08-02 | Vanderbilt University | Methods of preventing platelet activation |
| US10166248B1 (en) | 2015-12-21 | 2019-01-01 | Vanderbilt University | Methods of preventing platelet activation |
| AU2017293846B2 (en) * | 2016-07-06 | 2022-03-17 | Vanderbilt University | Use of scavengers of reactive gamma-ketoaldehydes to extend cell lifespan and healthspan |
| CN110022936A (zh) * | 2016-07-07 | 2019-07-16 | 范德比尔特大学 | 用γ-酮醛清除剂预防和治疗心房颤动/扑动 |
| EP3510014B1 (en) * | 2016-09-06 | 2026-04-29 | Metabolic Technologies, Inc. | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nash or ald |
| WO2018048937A1 (en) * | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| PL3541185T3 (pl) * | 2016-11-15 | 2024-08-12 | Vanderbilt University | Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu |
| US11389414B2 (en) | 2017-04-27 | 2022-07-19 | Vanderbilt University | Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers |
| US20210023032A1 (en) * | 2017-09-05 | 2021-01-28 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver |
| AU2018330416B2 (en) * | 2017-09-05 | 2024-09-26 | Mti Biotech, Inc. | Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving fibrosis of the liver |
| CN109836341B (zh) * | 2017-11-28 | 2021-08-27 | 江阴技源药业有限公司 | 一种水杨胺醋酸盐的制备方法 |
| US20200197323A1 (en) * | 2018-12-21 | 2020-06-25 | Vanderbilt University | Methods for suppressing accumulation of reflux-induced protein adducts |
| JP2023512225A (ja) * | 2020-01-27 | 2023-03-24 | ヴァンダービルト ユニバーシティー | ミトコンドリア標的イソケタール／イソレブグランジンスカベンジャー及びその使用 |
| CN118652245B (zh) * | 2024-08-21 | 2024-11-12 | 首都医科大学附属北京儿童医院 | 一种化合物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740439A (en) * | 1968-06-24 | 1973-06-19 | Ciba Geigy Corp | Treating hypertension with beta-aminoalkane carboxylic acids |
| US3794734A (en) * | 1971-03-03 | 1974-02-26 | Merck & Co Inc | Methods of treating edema and hypertension using certain 2-aminoethylphenols |
| US4123537A (en) * | 1977-05-26 | 1978-10-31 | Merck & Co., Inc. | 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema |
| US8178516B2 (en) * | 1992-06-30 | 2012-05-15 | Sylvan Labs, LLC | Compositions and method for treatment of chronic inflammatory diseases |
| US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| CA2219944A1 (en) | 1995-05-19 | 1996-11-21 | Miho Kobayashi | 2-hydroxyphenylalkylamine derivatives and maillard reaction inhibitors |
| US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
| EP1341532B1 (en) | 2000-11-02 | 2006-07-26 | University of South Carolina | Use of pyridoxamine for the treatment and inhibition of obesity-related complications |
| US6824786B2 (en) * | 2001-11-27 | 2004-11-30 | Ruey J. Yu | Compositions comprising phenyl-glycine derivatives |
| US7705054B1 (en) | 2004-10-20 | 2010-04-27 | Vanderbilt University | Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases |
| JP5547637B2 (ja) * | 2007-10-05 | 2014-07-16 | インデックス・ファーマシューティカルズ・アクチエボラーグ | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
| KR100973343B1 (ko) * | 2008-02-01 | 2010-07-30 | 롯데칠성음료주식회사 | 기호성이 우수한 혼합차 조성물 및 그 제조방법 |
| CN101305759B (zh) * | 2008-06-19 | 2011-09-07 | 成都大学 | 一种苦荞保健茶及其制备方法 |
| CN101843671A (zh) * | 2009-03-25 | 2010-09-29 | 王文祥 | 苦荞托毒丸及其制备方法 |
| WO2011008202A1 (en) * | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| CN101606986A (zh) * | 2009-07-29 | 2009-12-23 | 李钢 | 一种具有降糖作用的组合物及其药物 |
-
2012
- 2012-07-12 MX MX2014000515A patent/MX383365B/es unknown
- 2012-07-12 CA CA2844150A patent/CA2844150C/en active Active
- 2012-07-12 CN CN201280044440.6A patent/CN103796648B/zh active Active
- 2012-07-12 JP JP2014520341A patent/JP6280033B2/ja active Active
- 2012-07-12 HU HUE12811030A patent/HUE065757T2/hu unknown
- 2012-07-12 KR KR1020197016572A patent/KR102050700B1/ko active Active
- 2012-07-12 PL PL12811030.1T patent/PL2731597T3/pl unknown
- 2012-07-12 EP EP12811030.1A patent/EP2731597B1/en active Active
- 2012-07-12 AU AU2012281061A patent/AU2012281061B2/en active Active
- 2012-07-12 KR KR1020147003650A patent/KR20140050661A/ko not_active Ceased
- 2012-07-12 US US14/232,615 patent/US10975033B2/en active Active
- 2012-07-12 BR BR112014000810A patent/BR112014000810A8/pt not_active Application Discontinuation
- 2012-07-12 CN CN201910951171.5A patent/CN111494352A/zh active Pending
- 2012-07-12 WO PCT/US2012/046549 patent/WO2013010034A2/en not_active Ceased
- 2012-07-12 ES ES12811030T patent/ES2970814T3/es active Active
-
2021
- 2021-04-13 US US17/229,593 patent/US20210261508A1/en not_active Abandoned
-
2024
- 2024-10-16 US US18/917,789 patent/US20250214939A1/en active Pending
- 2024-10-16 US US18/917,759 patent/US20250034093A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE065757T2 (hu) | 2024-06-28 |
| US20250034093A1 (en) | 2025-01-30 |
| US20250214939A1 (en) | 2025-07-03 |
| MX383365B (es) | 2025-03-13 |
| ES2970814T3 (es) | 2024-05-30 |
| WO2013010034A2 (en) | 2013-01-17 |
| US20210261508A1 (en) | 2021-08-26 |
| EP2731597C0 (en) | 2023-12-20 |
| CA2844150C (en) | 2019-09-03 |
| JP2014524918A (ja) | 2014-09-25 |
| KR102050700B1 (ko) | 2019-11-29 |
| CA2844150A1 (en) | 2013-01-17 |
| CN111494352A (zh) | 2020-08-07 |
| MX2014000515A (es) | 2014-03-27 |
| US10975033B2 (en) | 2021-04-13 |
| EP2731597A4 (en) | 2015-04-08 |
| EP2731597B1 (en) | 2023-12-20 |
| EP2731597A2 (en) | 2014-05-21 |
| WO2013010034A3 (en) | 2013-03-28 |
| AU2012281061B2 (en) | 2017-08-03 |
| KR20190069607A (ko) | 2019-06-19 |
| PL2731597T3 (pl) | 2024-04-29 |
| CN103796648B (zh) | 2019-10-25 |
| KR20140050661A (ko) | 2014-04-29 |
| CN103796648A (zh) | 2014-05-14 |
| BR112014000810A2 (pt) | 2017-06-13 |
| US20140256774A1 (en) | 2014-09-11 |
| AU2012281061A1 (en) | 2014-02-20 |
| BR112014000810A8 (pt) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6280033B2 (ja) | ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法 | |
| US8008328B2 (en) | Methods for the treatment of diabetes-associated dyslipdemia | |
| US12060379B2 (en) | Plasmalogen derivatives | |
| JP2024063122A (ja) | 加齢に関連する状態の診断及び治療のための組成物及び方法 | |
| JP2017014284A (ja) | プテロスチルベンの抗不安効果 | |
| TW202337456A (zh) | Ｇｍ２神經節苷脂症之治療 | |
| JP2016512544A (ja) | ドコサペンタエン酸を含む組成物、および使用方法 | |
| JP2022046654A (ja) | γ－ケトアルデヒドスカベンジャーによるアテローム性動脈硬化症の治療方法 | |
| JP2008526861A (ja) | 炎症性障害を治療するための薬剤併用療法および医薬組成物 | |
| KR20140105598A (ko) | [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도 | |
| CN111344016B (zh) | 用于抑制胆碱向三甲胺(tma)的转化的方法 | |
| US20220370411A1 (en) | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | |
| US20050113443A1 (en) | Modulation of airway inflammation in patients with cystic fibrosis and related diseases | |
| HK40023703A (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
| EP3618834B1 (en) | Functionalized saccharides as anti-inflammatory agents | |
| JP6353159B2 (ja) | Ｔｌｒ非依存性低分子アジュバント | |
| HK1191859A (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
| HK1191859B (en) | Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers | |
| CN111163765A (zh) | 用于抑制胆碱向三甲胺(tma)的转化的方法 | |
| US20230355549A1 (en) | Method of preventing kidney injury disruption of intestinal lymphatics | |
| JP2016204303A (ja) | 抗健忘症用組成物 | |
| CN111163763A (zh) | 用于抑制胆碱向三甲胺(tma)的转化的方法 | |
| JP2003519196A (ja) | 炎症性疾患および呼吸器疾患を処置するための併用療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160510 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160926 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170307 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170802 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171215 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180118 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6280033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |